Replimune's Series B Round

Replimune raised a round of funding on September 08, 2017.

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the…

Articles about Replimune's Series B Round: